UltraPlasma™ Multi-Platform Plasma Systems for Shingles (Herpes Zoster) Treatment

#an Advanced Gas-Interactive Dermatological Approach#

Introduction

Shingles (Herpes Zoster) is a viral disease caused by the reactivation of the varicella-zoster virus. This condition primarily affects dermatomes and induces painful rashes, nerve damage, and long-term complications such as postherpetic neuralgia (PHN). Conventional treatments focus on antivirals and pain management but often fall short in regeneration and inflammation control.

UltraPlasma™ presents an advanced multi-platform plasma treatment device that integrates arc, argon, and helium plasma technologies—all harmonized by a proprietary software-hardware synergy. This next-generation system generates a tunable plasma emission spectrum tailored to dermatological and immunological interventions for shingles.

1. UltraPlasma™ System Overview

UltraPlasma™ combines:

• Arc Plasma: Delivers high-energy discharge, enabling deep epidermal penetration and virus denaturation.

• Argon Plasma: Offers moderate-temperature plasma jets enriched with reactive oxygen species (ROS).

• Helium Plasma: Generates cold plasma streams that stabilize the skin surface while enabling targeted delivery of NO (nitric oxide).

The integrated control software dynamically adjusts pulse frequency, voltage, gas flow rate, and plasma composition to create customized profiles for each skin layer and treatment stage.

2. UltraPlasma™ Interactions with Skin Layers

The human skin comprises three major layers: epidermis, dermis, and hypodermis—each with distinct roles in immune defense, vascular flow, and nerve signaling. Shingles-induced damage affects these layers differentially.

Epidermis (Surface Barrier & Viral Colonization)

• UltraPlasma™ arc plasma mode and ozone eliminate viral particles on surface.

• UltraPlasma™ cold helium plasma ensures antimicrobial effects without overheating.

Dermis (Vascular Response)

• Nitric oxide (NO) and oxygen radicals from plasma modulate local vasodilation.

• Stimulates microcirculation and macrophage-mediated immune clearance.

Hypodermis (Pain Modulation & Healing)

• Plasma-induced nitric oxide regulates neuroinflammation.

• Enhanced delivery of regenerative signals to peripheral nerves.

UltraPlasma™ Plasma Penetration

• Epidermis: High-intensity ozone/ROS contact

• Dermis: Controlled NO diffusion, capillary stimulation

• Hypodermis: Nerve regeneration, fat layer oxygenation

3. Reactive Species Generated by UltraPlasma™

UltraPlasma™ creates a customizable mix of biologically active gases:

• Ozone (O₃): Antiviral, oxidizes viral envelopes.

• Nitric Oxide (NO): Anti-inflammatory, pain modulator, vasodilator.

• Reactive Oxygen/Nitrogen Species (ROS/RNS): Promote tissue oxygenation and immune activity.

4. Clinical Applications and Results in Shingles

• Acute Lesion Management: Immediate plasma contact reduces viral replication and neutralizes vesicles.

• Pain Relief: NO-mediated neuromodulation decreases pain sensitivity.

• Accelerated Healing: Angiogenesis and fibroblast activity increase in dermis and hypodermis.

• Reduced PHN Risk: Early intervention reduces the chance of long-term nerve damage.

Figure 4: Treated Shingles Lesions – Before and After (UltraPlasma™ Protocol)
Side-by-side photos at Day 0 and Day 10 with visible reduction in inflammation and scabbing

Figure 3: Reactive Gases Output During UltraPlasma™ Treatment
showing the proportional distribution of O₃, NO, ROS, and RNS based on input gas and power levels.

5. Suggested Protocol Using UltraPlasma™

⌘Conclusion⌘

UltraPlasma™ offers a precision-controlled, multi-layer-targeted therapy for shingles by combining the strengths of arc, argon, and helium plasma technologies. Its ability to generate therapeutic gases like ozone and nitric oxide, alongside hardware-level control, makes it a next-generation dermatological solution. Clinical data support its efficacy in reducing lesion severity, accelerating healing, and preventing postherpetic neuralgia.

Shortcut for our Goals!

▼